About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company (NASDAQ:NAMS) is a dynamic enterprise dedicated to developing innovative solutions in the healthcare sector. At its core, the company focuses on creating and advancing a portfolio of therapeutic products aimed at addressing severe cardiometabolic diseases, a realm where patient needs are continuously evolving and growing. NewAmsterdam Pharma is committed to improving clinical outcomes and enhancing the quality of life for patients around the globe through its dedicated research, development, and commercialization efforts. The company's projects range from early-stage discovery to late-stage development, underlining its objective to deliver breakthrough treatments that can significantly impact public health. NewAmsterdam Pharma operates with a vision to become a pivotal player in transforming the management of cardiometabolic disorders, leveraging cutting-edge science and strategic partnerships to achieve its goals.
Snapshot
Operations
Products and/or services of NewAmsterdam Pharma Company N.V.
- Developing a novel oral cholesteryl ester transfer protein inhibitor for reducing cardiovascular risk.
- Focusing on therapies for metabolic and cardiovascular diseases.
- Advancing a pipeline of proprietary compounds for dyslipidemia management.
- Researching innovative approaches to treat non-alcoholic steatohepatitis (NASH).
- Exploring potential treatments for familial hypercholesterolemia.
- Expanding into the development of solutions for reducing triglyceride levels.
NewAmsterdam Pharma Company N.V. executive team
- Dr. Michael Harvey Davidson FACC, Facp., M.D.CEO, President & Executive Board Member
- Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.Founder, Chief Scientific Officer, Member of Executive Board & Director
- Mr. Mayur Amrat SomaiyaChief Financial Officer
- Mr. Douglas F. KlingChief Operating Officer
- Ms. Juliette Audet M.B.A., M.Sc.Chief Strategy & Business Officer
- Ms. Louise KooijChief Accounting Officer
- Mr. Matthew PhilippeExecutive VP &Head of Investor Relations
- Mr. Bob RamboExecutive Vice President of Marketing
- Ms. Maryellen McQuadeChief People Officer
- Dr. Marc Ditmarsch M.D.Chief Development Officer